Wall Street expects a year-over-year increase in earnings on higher revenues when Golar LNG (GLNG) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 25, might help the stock move higher if these key numbers are better than expecta ...

Company Overview - Catalyst Pharmaceutical (CPRX) is expected to report a year-over-year decline in earnings, with a projected earnings per share (EPS) of $0.42, reflecting a decrease of 40% compared to the previous year [3] - Revenues are anticipated to be $140.02 million, down 1.3% from the same quarter last year [3] Earnings Report Expectations - The earnings report is scheduled for release on February 25, and the actual results could significantly influence the stock price depending on whether they exceed or fall short of expectations [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Catalyst is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -47.93%, suggesting a bearish sentiment among analysts regarding the company's earnings prospects [11] - Despite the negative Earnings ESP, the stock holds a Zacks Rank of 3, making it challenging to predict a consensus EPS beat [11] Historical Performance - In the last reported quarter, Catalyst exceeded the expected EPS of $0.51 by delivering $0.68, resulting in a surprise of +33.33% [12] - Over the past four quarters, the company has consistently beaten consensus EPS estimates [13] Industry Context - Ionis Pharmaceuticals (IONS), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $1.21 per share, indicating a year-over-year change of -83.3% [17] - Ionis's revenues are projected to be $155.58 million, down 31.5% from the previous year, but it has an Earnings ESP of +17.84%, suggesting a higher likelihood of beating the consensus EPS estimate [18][19]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Kura Oncology, with a focus on how actual results compare to estimates impacting stock price [1] Earnings Expectations - Kura Oncology is expected to report a quarterly loss of $0.72 per share, reflecting a year-over-year change of -227.3% [3] - Revenues are projected to be $29.81 million, down 44.7% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 552.38% lower in the last 30 days, indicating a significant reassessment by analysts [4] - The Most Accurate Estimate for Kura Oncology is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.29% [12] Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with predictive power being significant for positive readings only [9][10] - Kura Oncology currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [12] Historical Performance - In the last reported quarter, Kura Oncology was expected to post a loss of $0.57 per share but actually reported a loss of -$0.85, resulting in a surprise of -49.12% [13] - Over the past four quarters, Kura has only beaten consensus EPS estimates once [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Apellis Pharmaceuticals is expected to report a loss of $0.39 per share, indicating a year-over-year change of -34.5% [18] - Apellis' revenue is projected to be $194.37 million, down 8.5% from the previous year, with an Earnings ESP of -3.07% [19][20]

Core Viewpoint - The market anticipates Mirum Pharmaceuticals, Inc. (MIRM) to report a year-over-year increase in earnings driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Earnings Expectations - The consensus EPS estimate for Mirum Pharmaceuticals is $0.02 per share, reflecting a year-over-year increase of +104.1% [3] - Expected revenues are projected to be $141.27 million, which is an increase of 42.1% compared to the same quarter last year [3] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 50.88% higher, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Mirum Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +675.00% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10] - Mirum Pharmaceuticals currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Mirum Pharmaceuticals was expected to post a loss of $0.1 per share but instead reported earnings of $0.05, resulting in a surprise of +150.00% [13] - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14] Industry Context - Another company in the same industry, Tarsus Pharmaceuticals, Inc. (TARS), is expected to report a loss of $0.19 per share, with revenues projected at $144.96 million, reflecting a year-over-year increase of 118.3% [18][19] - Tarsus Pharmaceuticals has an Earnings ESP of +136.84% and a Zacks Rank of 2 (Buy), suggesting a strong likelihood of beating the consensus EPS estimate [20]

Wall Street expects a year-over-year increase in earnings on higher revenues when Imax (IMAX) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 25, might help the stock move higher if these key numbers are better than expectations ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Sterling Infrastructure, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - Sterling Infrastructure is expected to report quarterly earnings of $2.66 per share, reflecting an increase of +82.2% year-over-year [3]. - Revenues are projected to reach $647.81 million, marking a growth of 29.9% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 3.89% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Sterling Infrastructure is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +2.01% [11]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [9]. - Sterling Infrastructure holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Sterling Infrastructure exceeded expectations by delivering earnings of $3.48 per share against an expected $2.79, resulting in a surprise of +24.73% [12]. - The company has consistently beaten consensus EPS estimates over the last four quarters [13]. Industry Context - In the Zacks Engineering - R and D Services industry, VSE is expected to report earnings of $0.88 per share, indicating a year-over-year decline of -2.2% [17]. - VSE's revenue is projected to be $294.6 million, down 1.5% from the previous year [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Marriott Vacations Worldwide due to lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected on February 25, with a consensus estimate of $1.72 per share, reflecting a year-over-year decrease of 7.5% [3]. - Revenues are projected to be $1.32 billion, down 0.2% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.94% higher in the last 30 days, indicating a reassessment by analysts [4]. - However, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.67%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is significant mainly for positive readings [9][10]. - The current Zacks Rank for Marriott Vacations Worldwide is 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, the company exceeded expectations with earnings of $1.69 per share against an estimate of $1.64, resulting in a surprise of +3.05% [13]. - Over the past four quarters, Marriott Vacations Worldwide has beaten consensus EPS estimates each time [14]. Industry Context - In the broader leisure and recreation services industry, Pursuit Attractions and Hospitality is expected to report a loss of $0.81 per share, with revenues projected to increase by 27.2% year-over-year [19]. - Pursuit Attractions and Hospitality has a negative Zacks Rank of 4, complicating predictions for an earnings beat despite a positive Earnings ESP of +4.94% [20].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for Permian Resources due to lower revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Permian Resources is expected to report quarterly earnings of $0.28 per share, reflecting a year-over-year decrease of 22.2% [3]. - Revenues are projected to be $1.29 billion, a slight decline of 0.3% compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 17.42% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Permian Resources is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.35% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with positive readings being more predictive of earnings beats [9][10]. - Permian Resources currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, Permian Resources exceeded the consensus EPS estimate of $0.30 by delivering earnings of $0.37, resulting in a surprise of +23.33% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Comparison - Gulfport Energy, a peer in the oil and gas exploration and production sector, is expected to report earnings of $5.77 per share, indicating a year-over-year increase of 20.2% [18]. - Gulfport's revenues are anticipated to reach $373.24 million, up 55.6% from the previous year, with an Earnings ESP of +3.02% suggesting a likely earnings beat [19][20].

Core Viewpoint - Bank of Montreal (BMO) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ending January 2026, with a consensus outlook suggesting a positive earnings picture [1] Earnings Expectations - The upcoming earnings report is expected to reveal quarterly earnings of $2.39 per share, reflecting an 11.7% increase year-over-year, and revenues are projected to be $6.63 billion, up 1.7% from the previous year [3] - The stock price may rise if these key figures exceed expectations, while a miss could lead to a decline [2] Estimate Revisions - The consensus EPS estimate has been revised 6.98% higher in the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing views from analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, with positive readings being more reliable [9][10] - The stock currently holds a Zacks Rank of 2, which complicates predictions of an earnings beat [12] Historical Performance - In the last reported quarter, BMO exceeded the expected earnings of $2.16 per share by delivering $2.36, resulting in a surprise of +9.26% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Conclusion - While BMO does not appear to be a strong candidate for an earnings beat, investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17]

Core Viewpoint - The market anticipates Dine Brands (DIN) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Dine Brands is expected to report quarterly earnings of $1.10 per share, reflecting a year-over-year increase of +26.4%, with revenues projected at $227.8 million, up 11.3% from the previous year [3]. - The earnings report is scheduled for release on February 25, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 0.92% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - Dine Brands currently has a negative Earnings ESP of -5.94%, suggesting analysts have become bearish on the company's earnings outlook [12]. Historical Performance - In the last reported quarter, Dine Brands was expected to post earnings of $0.82 per share but only achieved $0.73, resulting in a surprise of -10.98% [13]. - The company has not surpassed consensus EPS estimates in any of the last four quarters, indicating a trend of underperformance [14]. Industry Context - In the broader Zacks Retail - Restaurants industry, Cava Group (CAVA) is expected to report earnings of $0.03 per share for the same quarter, representing a year-over-year decrease of -40%, with revenues projected at $268.17 million, up 17.9% [18][19]. - Cava has an Earnings ESP of +36.11%, but its Zacks Rank of 4 (Sell) complicates predictions regarding its ability to beat consensus EPS estimates [20].